Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Non-muscle Invasive Bladder Cancer Patients: Initial Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor Setting

Lignende værker

• Should intravesical Bacillus Calmette–Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
  af: Yuk, Hyeong Dong, et al.
  Udgivet: (2018)
• Dose, duration and strain of bacillus Calmette–Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials
  af: Quan, Yongjun, et al.
  Udgivet: (2017)
• Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor
  af: Kang, Minyong, et al.
  Udgivet: (2016)
• Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating non‐muscle‐invasive bladder cancer
  af: Shepherd, Andrew RH, et al.
  Udgivet: (2017)
• Intravesical Bacillus Calmette‐Guérin in Ta and T1 bladder cancer
  af: Shelley, Mike, et al.
  Udgivet: (2000)